HK1208379A1 - Combined treatment with netrin-1 interfering drug and chemotherapeutic drug - Google Patents
Combined treatment with netrin-1 interfering drug and chemotherapeutic drug Download PDFInfo
- Publication number
- HK1208379A1 HK1208379A1 HK15109200.0A HK15109200A HK1208379A1 HK 1208379 A1 HK1208379 A1 HK 1208379A1 HK 15109200 A HK15109200 A HK 15109200A HK 1208379 A1 HK1208379 A1 HK 1208379A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- netrin
- drug
- interfering
- receptor
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261700158P | 2012-09-12 | 2012-09-12 | |
| EP12306100.4 | 2012-09-12 | ||
| EP12306100.4A EP2708231A1 (en) | 2012-09-12 | 2012-09-12 | Combined treatment with netrin-1 interfering drug and chemotherapeutic drug |
| PCT/EP2013/068937 WO2014041088A2 (en) | 2012-09-12 | 2013-09-12 | Combined treatment with netrin-1 interfering drug and chemotherapeutic drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1208379A1 true HK1208379A1 (en) | 2016-03-04 |
Family
ID=46924380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15109200.0A HK1208379A1 (en) | 2012-09-12 | 2013-09-12 | Combined treatment with netrin-1 interfering drug and chemotherapeutic drug |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9895439B2 (xx) |
| EP (2) | EP2708231A1 (xx) |
| JP (1) | JP6467604B2 (xx) |
| KR (1) | KR102424439B1 (xx) |
| CN (2) | CN110522913A (xx) |
| AU (1) | AU2013314320B2 (xx) |
| BR (1) | BR112015005443A2 (xx) |
| CA (1) | CA2884834C (xx) |
| ES (1) | ES2702733T3 (xx) |
| HK (1) | HK1208379A1 (xx) |
| IL (1) | IL237702B (xx) |
| MX (1) | MX375941B (xx) |
| SG (1) | SG11201501877WA (xx) |
| WO (1) | WO2014041088A2 (xx) |
| ZA (1) | ZA201502269B (xx) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2893939A1 (en) * | 2014-01-10 | 2015-07-15 | Netris Pharma | Anti-netrin-1 antibody |
| CN105031611B (zh) * | 2015-06-18 | 2018-02-09 | 中国医学科学院基础医学研究所 | netrin‑1蛋白在制备用于肿瘤治疗的药物中的用途 |
| TW201720459A (zh) | 2015-11-02 | 2017-06-16 | 妮翠斯製藥公司 | Ntn1中和劑與抑制後生控制之藥物之組合治療 |
| CN105861505A (zh) * | 2016-05-31 | 2016-08-17 | 东北师范大学 | 靶向沉默UNC5A的shRNA |
| CA3045302A1 (en) * | 2016-11-29 | 2018-06-07 | Health Research, Inc. | Methods and compositions for cancer therapy |
| WO2018127570A1 (en) | 2017-01-05 | 2018-07-12 | Netris Pharma | Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs |
| CN112812167B (zh) * | 2021-01-06 | 2023-04-11 | 东北师范大学 | 一种促进细胞存活的Netrin-1模拟肽、Netrin-1截短多肽及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4711955A (en) | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
| CA1223831A (en) | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
| US5792608A (en) | 1991-12-12 | 1998-08-11 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
| US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
| AU2001293870A1 (en) | 2000-10-16 | 2002-04-29 | Bayer Aktiengesellschaft | Regulation of human netrin binding membrane receptor unc5h-1 |
| US7312243B1 (en) * | 2003-08-29 | 2007-12-25 | Jay Pravda | Materials and methods for treatment of gastrointestinal disorders |
| US20060025335A1 (en) | 2004-01-30 | 2006-02-02 | Kinane Thomas B | Netrin compositions and methods of using the same |
| US20080038255A1 (en) | 2004-06-04 | 2008-02-14 | Aplied Research Systems Ars Holding N.V. | Splice Variant of Unc5h2 |
| AU2005275062A1 (en) | 2004-07-14 | 2006-02-23 | University Of Utah Research Foundation | Netrin-related compositions and uses |
| WO2006054000A2 (fr) * | 2004-11-22 | 2006-05-26 | Centre National De La Recherche Scientifique | Netrine 4 mutee, ses fragments et leur utilisation comme medicaments |
| US20060153840A1 (en) | 2005-01-12 | 2006-07-13 | Anne Eichmann | Methods for preventing or treating a condition or a disease associated with angiogenesis |
| WO2007099133A1 (en) | 2006-02-28 | 2007-09-07 | Centre National De La Recherche Scientifique (Cnrs) | Screening for anti-cancer compounds using netrin-1 activity |
| WO2009141440A1 (en) | 2008-05-21 | 2009-11-26 | Centre National De La Recherche Scientifique (Cnrs) | Netrin-1 overexpression as a biological marker and a survival factor for aggressive neuroblastoma |
| AR074369A1 (es) * | 2008-11-20 | 2011-01-12 | Genentech Inc | Anticuerpos anti-unc 5b (receptor de netrina) y metodos de uso |
| EP2208738A1 (en) * | 2009-01-09 | 2010-07-21 | Centre National pour la Recherche Scientifique (CNRS) | Method for the selection of endothelial cells death inducers via netrin-1 and its applications |
| MX2013001836A (es) | 2010-08-26 | 2013-07-29 | Hoffmann La Roche | Proteina de fusion de fc recombinante del quinto dominio tipo iii de fibronectina de ddc. |
-
2012
- 2012-09-12 EP EP12306100.4A patent/EP2708231A1/en not_active Withdrawn
-
2013
- 2013-09-12 CA CA2884834A patent/CA2884834C/en active Active
- 2013-09-12 HK HK15109200.0A patent/HK1208379A1/xx unknown
- 2013-09-12 JP JP2015531561A patent/JP6467604B2/ja active Active
- 2013-09-12 MX MX2015003343A patent/MX375941B/es active IP Right Grant
- 2013-09-12 BR BR112015005443A patent/BR112015005443A2/pt not_active Application Discontinuation
- 2013-09-12 US US14/427,426 patent/US9895439B2/en active Active
- 2013-09-12 SG SG11201501877WA patent/SG11201501877WA/en unknown
- 2013-09-12 EP EP13763033.1A patent/EP2895173B1/en active Active
- 2013-09-12 ES ES13763033T patent/ES2702733T3/es active Active
- 2013-09-12 WO PCT/EP2013/068937 patent/WO2014041088A2/en not_active Ceased
- 2013-09-12 CN CN201910781061.9A patent/CN110522913A/zh active Pending
- 2013-09-12 CN CN201380051861.6A patent/CN104853756A/zh active Pending
- 2013-09-12 AU AU2013314320A patent/AU2013314320B2/en active Active
- 2013-09-12 KR KR1020157009344A patent/KR102424439B1/ko active Active
-
2015
- 2015-03-12 IL IL237702A patent/IL237702B/en active IP Right Grant
- 2015-04-07 ZA ZA2015/02269A patent/ZA201502269B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013314320A1 (en) | 2015-04-02 |
| MX2015003343A (es) | 2015-10-22 |
| IL237702B (en) | 2018-11-29 |
| AU2013314320A2 (en) | 2015-04-09 |
| CA2884834A1 (en) | 2014-03-20 |
| EP2895173B1 (en) | 2018-11-14 |
| KR102424439B1 (ko) | 2022-07-21 |
| CA2884834C (en) | 2020-11-17 |
| JP2015529675A (ja) | 2015-10-08 |
| MX375941B (es) | 2025-03-07 |
| WO2014041088A2 (en) | 2014-03-20 |
| EP2895173A2 (en) | 2015-07-22 |
| US9895439B2 (en) | 2018-02-20 |
| ES2702733T3 (es) | 2019-03-05 |
| EP2708231A1 (en) | 2014-03-19 |
| CN110522913A (zh) | 2019-12-03 |
| ZA201502269B (en) | 2019-05-29 |
| WO2014041088A3 (en) | 2014-07-03 |
| JP6467604B2 (ja) | 2019-02-13 |
| US20150246116A1 (en) | 2015-09-03 |
| CN104853756A (zh) | 2015-08-19 |
| KR20150079599A (ko) | 2015-07-08 |
| AU2013314320B2 (en) | 2017-04-06 |
| BR112015005443A2 (pt) | 2017-12-05 |
| SG11201501877WA (en) | 2015-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7600286B2 (ja) | 抗癌療法としての正常細胞および腫瘍細胞の小分子ｔｒａｉｌ遺伝子誘導 | |
| CN110546277B (zh) | 用于癌症的诊断和治疗方法 | |
| JP6591428B2 (ja) | 癌治療のためのｐｄ−１拮抗薬およびｖｅｇｆｒ阻害剤の組み合わせ | |
| US9895439B2 (en) | Combined treatment with netrin-1 interfering drug and chemotherapeutic drug | |
| EP3202419A1 (en) | Pvrig binding agents that modulate the hippo pathway and uses thereof | |
| KR20180119632A (ko) | 암에 대한 치료 및 진단 방법 | |
| JP2020534296A (ja) | ネトーシスおよび好中球活性化を処置するための方法 | |
| KR20210041571A (ko) | 역형성 림프종 키나아제 억제제와 조합하여 egf/egfr 경로를 억제하기 위한 방법 및 조성물 | |
| KR20220119562A (ko) | Egfr 표적 제제에 대한 저항성을 억제하기 위한 조성물 | |
| US20230227823A1 (en) | Fmrp and cancer treatment | |
| US9963701B2 (en) | Pharmaceutical composition for treatment of radiation- or drug-resistant cancer comprising HRP-3 inhibitor | |
| US20150147340A1 (en) | Therapeutic methods for peritoneal carcinomatosis | |
| JP5695905B2 (ja) | Ｎｌｒｒ−１アンタゴニスト及びその使用 | |
| JP2010540653A5 (xx) | ||
| KR20190040585A (ko) | Human Stm1 (hStm1) 유전자의 발현 또는 hSTM1 단백질의 활성을 억제하는 물질을 포함하는, 위암의 예방 또는 치료용 약학적 조성물 | |
| JP7254020B2 (ja) | 融合遺伝子を含有するがんを治療する方法 | |
| EP3787686A1 (en) | Therapeutic combination |